Synthesis, physicochemical properties and biological evaluation of aromatic ester prodrugs of 1-(2'-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): Orally active iron chelators with clinical potential

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 5, 1999, Pages 555-564

  Liu, Zu Dong ^a   Liu, Ding Yong ^a   Lu, Shu Li ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 3 HYDROXY 1 (2 HYDROXYETHYL) 4 PYRIDINONE; FERRITIN; IRON CHELATING AGENT; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; BLOOD; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG SYNTHESIS; LIPOPHILICITY; LIVER HOMOGENATE; NONHUMAN; ORAL DRUG ADMINISTRATION; PH; PHYSICAL CHEMISTRY; RAT;

EID: 0033029826     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991772655     Document Type: Conference Paper

References (28)

1. Ansel, L. P., Levy, G. (1969) Drug biotransformation interactions in man II. A pharmacokinetics study of the simultaneous conjugation of benzoic and salicylic acids with glycine. J. Pharm. Sci. 58: 321-326
2. Batshaw, M. L., Brusilow, S. W., Blom, W., Brubakk, A. M., Burton, B. K., Cann, H. M., Kerr, D., Mamuners, P., Matalon, R., Myerberg, D., Shafer, I. A. (1982) Treatment of inborn errors of urea synthesis. N. Engl. J. Med. 306: 1387-1392
3. Borshop, B. A., Breuer, J., Holm, J., Leslie, J., Nyhan, W. L. (1989) Excretion of hippuric acid during sodium benzoate therapy in patient with hyperglycinaemia. J. Inher. Dis. 12: 72-79
4. Brusilow, S. W., Valle, D. L., Batshaw, M. L. (1979) New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet ii: 452-454
5. Choudhury, R. (1995) Metabolism and Pharmacokinetics of 1-Hydroxyalkyl-3-hydroxypyridin-4-one Chelating Agents. Ph.D. Thesis, King's College, London
6. Choudhury, R., Epemolu, R. O., Rai, B. L., Hider, R. C., Singh, S. (1997) Metabolism and pharmacokinetics of 1-(2′-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Drug Metab. Disposit. 25: 332-339
7. Holme, E., Greter, J., Jacobson, C. E., Nordin, I., Lindstedt, S., Kristiansson, B. (1989) Carnitine deficiency induced by pivampicillin and pivampicillinam therapy. Lancet ii: 469-472
8. Holme, E., Jodal, U., Linstedt, S., Nordin, I. (1992) Effects of pivalic acid-containing prodrugs on carnitine homeostasis and on response to fasting in children. Scand. J. Clin. Invest. 52: 361-372
9. Jin, Y., Singh, S., Epemolu, R. O., Porter, J. B., Hider, R. C., Nick, H. P., Bergeron, R. J., Wiegand, J., Schnebli, H. P. (1993) CP102; a potent orally active iron chelator. Proceedings of the European Iron Club Meeting, London
10. 59Fe-ferritin loaded rat model. Biochem. Pharmacol. 57: 559-566
11. Melegh, B., Kerner, J., Bieber, L. L. (1987) Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem. Pharmacol. 36: 3405-3409
12. Mitsunobu, O. (1981) The use of diethylazodicarboxylate and triphenylphosphine in synthesis and transformation of nature products. Synthesis 1: 1-28
13. Oliveri, N. F., Koren, G., Matsui, D., Liu, P. P., Blendis, L., Cameron, R., McClelland, R. A., Templeton, D. M. (1992) Reduction in tissue iron stores and normalisation of serum ferritin during treatment with the oral iron chelator L1 in thalassaemia intermedia. Blood 79: 2741-2748
14. Pippard, M. J., Callender, S. T., Letsky, E. A., Weatherall, D. J. (1978a) Prevention of iron loading in transfusion-dependent thalassaemia. Lancet i: 1178-1180
15. Pippard, M. J., Callender, S. T., Weatherall, D. J. (1978b) Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias. Clin. Sci. Mol. Med. 54: 99-106
16. Pippard, M. J., Johnson, D. K., Finch, C. A. (1981) A rapid assay for evaluation of iron chelating agents in rats. Blood 58: 685-692
17. Poon, K., Pang, K. S. (1995) Benzoic acid glycine conjugation in the isolated perfused rat kidney. Drug Metab. Disposit. 23: 255-260
18. Porter, J. B., Huehns, E. R., Hider, R. C. (1989) The development of iron chelating drugs. Bailliere's Clin. Haematol. 2: 257-292
19. Porter, J. B., Morgan, J., Hoyes, K. P., Burke, L. C., Huehns, E. R., Hider, R. C. (1990a) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76: 2389-2396
20. Porter, J. B., Huehns, E. R., Hider, R. C. (1990b) Update on the hydroxypyridinone oral-iron chelating agents. Seminars in Haematology 27: 95-100
21. Porter, J. B., Abeysinghe, R. D., Hoyes, K. P., Barra, C., Huehns, E. R., Brooks, P.N., Blackwell, M. P., Araneta, M., Britenham, G., Singh, S., Dobbin, P., Hider, R. C. (1993) Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one CP94, relates to differing metabolism of the iron chelating site. Br. J. Haematol. 85: 159-168
22. Porter, J. B., Singh, S., Katherine, P. H., Epemolu, O., Abeysinghe, R. D., Hider, R. C. (1994) Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. Adv. Exp. Med. Biol. 356: 361-370
23. Rai, B. L., Dekhordi, L. S., Khodr, H., Jin, Y., Liu, Z., Hider, R. C. (1998) Synthesis, physicochemical properties and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones. J. Med. Chem. 41: 3347-3359
24. Rai, B. L., Liu, Z. D., Liu, D. Y., Lu, S. L., Hider, R. C. (1999) Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential. Eur. J. Med. Chem. In press
25. Singh, S., Epemolu, O., Dobbin, P. S. Tilbrook, G. S., Ellis, B. L., Damani, L. A. Hider, R. C. (1992a) Urinary metabolic profiles in man and rat of 1,2-dimethyl- and 1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metab. Disposit. 20: 256-261
26. Singh, S., Epemolu, R. O., Ackerman, R., Porter, J. B., Hider, R. C. (1992b) Development of 3-hydroxypyridin-4-ones which do not undergo extensive phase II metabolism. 3rd NIH-Sponsored Symposium on The Development of Iron Chelators for Clinical Use, Gainsville, FL, Abstract No. 52
27. Singh, S., Choudhury, R., Epemolu, R. O., Hider, R. C. (1996) Metabolism and pharmacokinetics of 1-(2′-hydroxyethyl)- and 1-(3′-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat. Eur. J. Drug Metab. Pharmacokinet. 21: 33-41
28. Tilbrook, G. S., Hider, R. C. (1998) Iron chelators for clinical use. In: Sigel, A., Sigel, H. (eds) Metal Irons in Biological Systems. Vol. 35. Iron Transport and Storage in Microorganisms, Plants and Animals. Marcel Dekker, New York, pp 691-730